Bladder cancer · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | 5.4 mo | — | 52 | R 14 921 674 PFS proxy | 1 |
Avelumab monotherapy Variant #01 Partial | — | — | 14d | — | 23.8 mo | 2 | — | 1 |
2 of 2 regimens shown